1. Pyronaridine induces apoptosis in non‐small cell lung cancer cells by upregulating death receptor 5 expression and inhibiting epidermal growth factor receptor.
- Author
-
Zhong, Zheng‐Hong, Yi, Ze‐Lin, Zhao, Yi‐Dan, Wang, Jue, Jiang, Ze‐Bo, Xu, Cong, Xie, Ya‐Jia, He, Qi‐Da, Tong, Zi‐Yan, Yao, Xiao‐Jun, Leung, Elaine Lai‐Han, Coghi, Paolo Saul, Fan, Xing‐Xing, and Chen, Min
- Subjects
- *
NON-small-cell lung carcinoma , *EPIDERMAL growth factor receptors , *DEATH receptors , *TRAIL protein , *CANCER cells , *CELL death - Abstract
Lung cancer is the leading cause of cancer death. Pyronaridine, a synthetic drug of artemisinin, has been used in China for over 30 years for the treatment of malaria, but its effect on non‐small cell lung cancer (NSCLC) cells is rarely reported. In this study, we determined the efficacy of pyronaridine in four different NSCLC cell lines and explored its mechanism in H1975. The data showed that pyronaridine could upregulate the expression of TNF‐related apoptosis‐inducing ligand (TRAIL)‐mediated death receptor 5 to promote cellular apoptosis. Meanwhile, the JNK (c‐Jun N‐terminal kinase) level was detected to be significantly increased after treating with pyronaridine. We used JNK inhibitor and found that it could partially inhibit cell apoptosis. The results showed that epidermal growth factor receptor (EGFR), PI3K, and AKT were downregulated after the treatment of pyronaridine. In summary, pyronaridine can selectively kill NSCLC by regulating TRAIL‐mediated apoptosis and downregulating the protein level of EGFR. It is a promising anticancer drug for NSCLC. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF